X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Low-value health care costs $345B each year and provides little benefit

By Katie Koziara  |    February 26, 2020
Low-value health care is treatment that offers little to no clinical benefit to patients yet is a major drain of resources often at the detriment to patients. Low-value health care is one of the...   Read More

Rare Disease Day 2020: Progress toward cures

By Richard Moscicki, M.D.  |    February 24, 2020
Today kicks off Rare Disease Week, an annual opportunity to celebrate the incredible progress that has been made to treat rare diseases and reflect on the need for continued research and...   Read More

Addressing barriers that inhibit value-based contracts

By Katie Koziara  |    February 21, 2020
With 56 new medicines approved by the U.S. Food and Drug Administration (FDA) in 2019 and over 8,000 medicines in development around the globe, innovative medicines are transforming the way we...   Read More

Helping those affected by the coronavirus

By Stephen J. Ubl  |    February 20, 2020
Updated as of 4/9/2020 America’s biopharmaceutical companies are committed to developing solutions to help diagnose and treat those with COVID-19, a disease caused by a novel strain of coronavirus...   Read More

Fact Check: HCCI analysis overstates medicine spending and prices

By Katie Koziara  |    February 19, 2020
A recent analysis from the Health Care Cost Institute (HCCI) on health care spending overestimates medicine spending and pricing and mischaracterizes the true drivers of health care spending in...   Read More

IP Explained: Four key takeaways from new Bayh-Dole white paper

By Tom Wilbur  |    February 19, 2020
2020 marks the 40th anniversary of the Bayh-Dole Act being signed into law. The Bayh-Dole Act laid the foundation for effective technology transfer that modernized the U.S. economy, set a global...   Read More

R&D Focus: New report shows nearly 600 medicines in development for pediatric patients

By Andrew Powaleny  |    February 13, 2020
America’s biopharmaceutical researchers are committed to studying, developing and testing medicines to meet the unique needs of pediatric patients. New treatment options for infants, children and...   Read More

New report: Biopharmaceutical industry supports over 4 million jobs and $1.1 trillion in U.S. economic output

By Sarah Sutton  |    February 12, 2020
Across the country, the biopharmaceutical sector supports millions of jobs in its pursuit to discover ground-breaking treatments and cures for patients around the world.   Read More

Trump administration must defend and protect U.S. innovation

By Priscilla VanderVeer  |    February 6, 2020
PhRMA recently submitted comments to the Office of the United States Trade Representative (USTR)’s Special 301 Report, calling on the Trump administration to defend American biopharmaceutical...   Read More

Working together to combat coronavirus

By Richard Moscicki, M.D.  |    February 6, 2020
The World Health Organization (WHO) recently declared the outbreak of 2019-nCoV, a novel strain of coronavirus that originated in Wuhan, China, a global health emergency. In the last three weeks,...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates